In addition, the fibrosis protein marker α-SMA was significantly downregulated in the 2-APQC treatment group, indicating that 2-APQC can alleviate myocardial fibrosis (Fig. 3d, f). Here, ACTA1 is linked to Myocardial fibrosis.